Stay updated on MK-2870-004 Clinical Trial

Sign up to get notified when there's something new on the MK-2870-004 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MK-2870-004 Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.6.5 and has removed the Plain Language Summary as well as the previous Revision: v3.6.4, indicating an update to the page's revision metadata.
    Difference
    0.0%
    Check dated 2026-08-09T00:12:07.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The page revision label was updated from v3.6.3 to v3.6.4, indicating an incremental release of the site. No visible content changes for the study details are described in the provided changes.
    Difference
    0.0%
    Check dated 2026-07-25T16:55:09.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    July 2026 update dates were added to the study record and June 2026 dates were removed, updating the record's modification history to reflect recent changes.
    Difference
    0.1%
    Check dated 2026-07-18T15:38:41.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The page revision updated from v3.6.2 to v3.6.3, indicating a new version of the study record. This likely reflects minor edits or corrections to the page.
    Difference
    0.0%
    Check dated 2026-07-04T04:50:49.000Z thumbnail image
  6. Check
    45 days ago
    Change Detected
    Summary
    Revision: v3.6.2 is now shown on the page, indicating an updated version of the page. This reflects a minor revision to the page rather than a substantive content change.
    Difference
    0.0%
    Check dated 2026-06-27T03:01:57.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    Adds a detailed study purpose describing the comparison between sacituzumab tirumotecan and chemotherapy for NSCLC with EGFR mutations or other genomic alterations, and introduces explicit primary and secondary endpoints (OS and PFS) with definitions and time frames; older language about multiple primary hypotheses has been removed.
    Difference
    0.3%
    Check dated 2026-06-19T22:09:48.000Z thumbnail image

Stay in the know with updates to MK-2870-004 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MK-2870-004 Clinical Trial page.